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Small Randomized Trials
Mary Redman, PhD,* and John Crowley, PhD,†
In this issue of the Journal, Buchholz et al.1 report on a trial that addresses the issue ofdose-intensity in the treatment of small cell lung cancer. The study was initially planned
as a 40-patient (evidently randomized) phase II pilot and then was amended (because of
promising interim results?) to include a maximum of 58 eligible patients per arm. The
study was stopped with a total of 83 eligible patients on the third of five further planned
interim analyses when the p value for the primary endpoint of 2-year survival was less
than the stated boundary of 0.01 (the final report gives this p value as 0.15, but a log rank
p value for overall survival of 0.001). Although we have some concerns regarding the
design and reporting of study results, we focus here on the properties of small randomized
studies.
Small randomized trials can arise from overly optimistic specification of the benefit
to be detected in a phase III trial (the idea that a “home run” is the only worthwhile hit);
from planned or unplanned interim analyses of phase III trials, after too few events; or
from the idea that phase II trials, which seek evidence of efficacy to justify a definitive
randomized comparison, need also be randomized. Such trials are characterized as having
a high false-negative rate, so that treatments associated with a clinically meaningful
benefit are missed and by having misleadingly large and unstable estimates of benefit for
those trials that are reported as positive. Both of these issues are illustrated by a recent
literature-based meta-analysis of trials of neoadjuvant chemotherapy versus surgery alone
for patients with non-small cell lung cancer, reported by Burdette et al.2 Of seven trials
with data that could be abstracted form the primary articles, five had sample sizes ranging
from 26 to 90 (the other two were much larger). All were negative, despite a combined
estimate of benefit of an 18% reduction in hazard for neoadjuvant therapy. Further, two
of the trials were stopped early at unplanned interim analyses, based on very small p
values and impressive estimates of benefit, but with further follow-up, the evidence of
benefit in both trials was not statistically significant.
There is now increasing pressure to move new agents through the investigational
and approvals processes more quickly. A proposed solution when looking for early
evidence of benefit is the now fashionable randomized phase II design. The use of
randomized phase II studies is typically motivated by settings where there are few
historical data on the expected efficacy of the standard of care in a population, clinical
outcomes may be heavily influenced by patient selection, and/or supportive care has
changed enough since previous studies that outcomes are expected to have been affected
in the target population.3 Design considerations for such trials are given by Rubenstein et
al.,4 who suggest increasing the false-positive rate to reduce the false-negative rate, but the
caveats given in that article as to the proper setting for randomization in phase II trials are
often ignored. One of the discussed contraindications is when a comparison of a new to
a standard treatment with regard to an endpoint appropriate for a phase III trial is intended,
as opposed to selecting the better (or best) of competing regimens to be later tested against
a standard.5 When such comparisons are the intent, the randomized phase II trial becomes
just a small phase III trial.
As previously mentioned, in addition to problems related to high false-negative
rates, treatment effect estimates and p values can be very unstable in small studies. For
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example, with 40 patients per arm and in truth the proportion
responding in both treatment arms is 40%, there is a 36%
chance of seeing greater than a 10% difference in response
proportions and an 19% chance of seeing greater than a 15%
difference in response proportions. It seems important to note
that most randomized phase II studies include fewer patients
than randomized phase III studies at their first interim anal-
ysis and the former usually uses a significance level of 0.05,
whereas the latter typically uses a much more conservative
level such as 0.005. The standard of evidence of early benefit
in a randomized phase III is usually much stricter.
The stated justifications for using a randomized phase II
design have some merits, but this design is not the only
approach to address these issues. If outcomes are potentially
heavily influenced by patient selection, then the use of strict
eligibility criteria should minimize the effects of patient
selection. If no historical data are available, sequential or
concurrent single-arm phase II studies could be performed.
Existing data can also be standardized to the target population
to obtain estimates of the efficacy of the standard treatment in
this population. Typically, these data are available from a
previous randomized phase III study, and therefore the avail-
able data will include a larger sample size than a control arm
from a randomized phase II, providing potentially more
precise historical estimates. The argument is often made
that if response rate is not an appropriate phase II endpoint
with the newer cytostatic agents, then phase II trials must
be randomized, but historical data do exist for other
endpoints such as progression-free survival or disease
control rate in the databases of the cooperative groups (see,
for example, Francart et al6).
The goal of randomization is to balance potentially
prognostic and predictive factors between the two (or more)
treatment arms so that the only substantial difference between
the two groups is the assigned treatment. Small randomized
studies do not necessarily achieve this balance, particularly
when the number of factors is large. The common practice of
testing for imbalances between arms does not necessarily
always reveal imbalances when they exist because, as small
studies are underpowered to detect differences in the main
outcome of interest, they are also underpowered to detect
other differences. Imbalances can be somewhat addressed in
the analysis, but treatment effect estimates may still be
confounded due to model misspecification of known factors.
Further, unknown prognostic factors likely exist and may be
unbalanced in small studies.
In summary, small randomized studies are likely to
result in false leads and missed opportunities. Estimates of
efficacy are unstable and therefore may not provide good data
on which to base further research. Perhaps the most serious
consequence, small randomized trials may actually preclude
subsequent definitive comparisons, either by yielding a false-
negative result or by resulting in a misleadingly positive one.
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